LEXXHealthcare · BiotechnologyTicker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 19 of 100 as at 31 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Lexaria Bioscience Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (93): Smaller than most of the companies we track.
Quality (10): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on LEXX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 26 Dec 2025 | HC Wainwright & Co. | Maintains | Buy | $4.00 → $1.50 |
| 29 July 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 1 July 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 24 Jan 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 2 Dec 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 25 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 18 July 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 10 July 2024 | HC Wainwright & Co. | Initiates | Buy | — |
| 5 Mar 2024 | Maxim Group | Maintains | Buy | — |
| 21 July 2023 | Maxim Group | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
LEXX appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 30 Oct 2026, Lexaria Bioscience Corp. returned −76.4% against +12.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 80% of US stocks
Cheaper than 6% of US stocks
Cheaper than 63% of US stocks
Cheaper than 64% of US stocks
Higher than 1% of US stocks
Higher than 3% of US stocks
Higher than 99% of US stocks
Higher than 9% of US stocks
Higher than 4% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Lexaria Bioscience Corp. has a market value of $7.4M and an enterprise value of $1.8M.
Revenue in the twelve months to 31 May 2026: $194K. The latest quarter shrank 100.0% year on year.
Net income over the same four quarters: −$7.7M, a −3989.9% net margin.
Free cash flow in the twelve months to 31 May 2026: −$7.5M.
Trailing P/E: −0.3×; forward P/E: −8.9× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Lexaria Bioscience Corp. employs 7 people — $28K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Lexaria Bioscience Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Lexaria Bioscience announced it has received its 70th patent, with new patents awarded in the US, Canada, and Europe. The patents cover intellectual property for treatments for epilepsy, diabetes, and hypertension.
Why it matters — The patent awards add to LEXX’s reported intellectual-property portfolio in these treatment areas.
Lexaria Bioscience reported that Human Pilot Study #7 (GLP-1-H26-7) has reached full enrollment, with dosing continuing on schedule. The study compares two oral DehydraTECH-semaglutide compositions with commercially available Wegovy tablets over five weeks.
Why it matters — The update provides LEXX watchers with a status report on enrollment and dosing for the company’s semaglutide study.
Lexaria reported results from animal study GLP-1-A26-1, which evaluated formulation enhancements involving DehydraTECH-CBD and DehydraTECH-semaglutide. The company highlighted a 566% improvement in brain absorption of DehydraTECH-CBD and said it had filed three patent applications related to the formulations.
Why it matters — The results and related patent filings provide LEXX watchers with an update on the company’s drug-delivery research and intellectual-property activity.
The report says the oral GLP-1 market is projected to grow from $5.1 billion in 2026 to $89 billion in 2034. It also reports that Novo announced additional weight loss among patients switching from injected to oral delivery.
Why it matters — The shift toward oral GLP-1 medications is relevant to LEXX watchers tracking changes in drug delivery across the weight-loss and diabetes industries.
Lexaria Bioscience Corp. issued an update stating it is in a strong cash position, supported by a recently announced Australian tax refund and an institutional financing round priced at US$12.92 per share. The company described the update in connection with its drug delivery platform work.
Why it matters — LEXX watchers would care because the update signals the company has strengthened its cash position through the Australian tax refund and institutional financing.
As at 31 Oct 2026, Lexaria Bioscience Corp. ranks 19 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (93 of 100).
No analyst covering Lexaria Bioscience Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LEXX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $82 to $82 over the next 12 months.
Lexaria Bioscience Corp. returned -76.4% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Lexaria Bioscience Corp. is a biotechnology company focused on improving how active pharmaceutical ingredients are delivered and absorbed in the body.
The most recent item we track (TheNewswire, 28 Oct 2026): "Lexaria Celebrates its 70th Patent Award". Lexaria Bioscience announced it has received its 70th patent, with new patents awarded in the US, Canada, and Europe. The patents cover intellectual property for treatments for epilepsy, diabetes, and hypertension.
Lexaria Bioscience Corp. is a biotechnology company focused on improving how active pharmaceutical ingredients are delivered and absorbed in the body. Its core platform, DehydraTECH, is designed to enhance oral bioavailability and can be applied across a range of compounds, including cannabinoids, nicotine, vitamins, pain medications, hormones, antivirals, and other lipophilic molecules. The company works through intellectual property licensing, business-to-business product development, and research and development activities, supporting pharmaceutical, nutraceutical, and consumer health applications. Lexaria Bioscience Corp. is headquartered in Kelowna, British Columbia, Canada, and its current work centers on developing and licensing drug delivery technologies for partners seeking more efficient oral formulations and improved therapeutic performance.
CEO Mr. Richard C. Christopher · 7 employees · Canada · https://lexariabioscience.com
